The earnings call presents several challenges: regulatory hurdles, competition from PAPZIMEOS, and cash limitations. Despite some positive feedback on INO-3107, the financials show a shrinking cash position and ongoing net losses. The Q&A reveals uncertainties around FDA timelines and competitive strategies. These factors, combined with the absence of strong financial metrics or guidance, suggest a negative sentiment and potential stock price decline.